Argus Research Upgrades Elevance Health to Buy, Announces $510 Price Target
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsUpgradesPrice TargetHot
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Argus Research analyst David Toung upgrades Elevance Health (NYSE:ELV) from Hold to Buy and announces $510 price target.
Argus Research analyst David Toung upgrades Elevance Health (NYSE:ELV) from Hold to Buy and announces $510 price target.
